Baird analyst Brian Skorney raised the firm’s price target on Axsome Therapeutics (AXSM) to $246 from $241 and keeps an Outperform rating on the shares. The firm updated its model following solid Q1 results with full steam ahead into ADA launch.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $290 from $270 at H.C. Wainwright
- Axsome Therapeutics price target raised to $276 from $239 at BofA
- Buy Rating Reiterated as Auvelity’s Expanded Alzheimer’s Opportunity Drives Upgraded $276 Price Target
- Axsome Therapeutics Earnings Call Signals Aggressive Growth
- Axsome Therapeutics price target raised to $280 from $250 at Oppenheimer